Lorcaserin
Lorcaserin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C. In addition, it is known to target 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 2B.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| belviq xr extended release | New Drug Application | 2016-07-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| obesity | EFO_0001073 | D009765 | E66.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 3 | 5 | 3 | 2 | 16 |
| Overweight | D050177 | E66.3 | — | — | 1 | 3 | 1 | 5 | |
| Weight gain | D015430 | HP_0004324 | 1 | 1 | — | 1 | — | 2 | |
| Weight loss | D015431 | HP_0001824 | — | — | — | 1 | 1 | 2 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | 1 | — | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | — | 1 |
| Psychotic disorders | D011618 | F20.81 | — | — | — | 1 | — | 1 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Smoking cessation | D016540 | EFO_0004319 | — | 3 | 1 | — | — | 3 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | 1 | 1 | — | — | 3 |
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | — | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | F14 | 5 | 3 | — | — | — | 7 | |
| Tobacco use disorder | D014029 | F17 | 1 | 3 | — | — | — | 3 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
| Tobacco smoking | D000073869 | — | 1 | — | — | — | 1 | ||
| Sepsis | D018805 | A41.9 | 1 | 1 | — | — | — | 1 | |
| Muscle weakness | D018908 | HP_0001324 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Digestive system neoplasms | D004067 | 1 | — | — | — | — | 1 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 | ||
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug resistant epilepsy | D000069279 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LORCASERIN |
| INN | lorcaserin |
| Description | Lorcaserin is a benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine substituted at position 1 by a methyl group and a t position 6 by a chloro group. It has a role as an appetite depressant and an anti-obesity agent. It is an organochlorine compound and a benzazepine. |
| Classification | Small molecule |
| Drug class | serotonin receptor agonists, primarily 5-HT2 |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1CNCCc2ccc(Cl)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 616202-92-7 |
| RxCUI | 1300701 |
| ChEMBL ID | CHEMBL360328 |
| ChEBI ID | 65353 |
| PubChem CID | 11658860 |
| DrugBank | DB04871 |
| UNII ID | 637E494O0Z (ChemIDplus, GSRS) |
Target
Agency Approved
HTR2C
HTR2C
Organism
Homo sapiens
Gene name
HTR2C
Gene synonyms
HTR1C
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2C
Protein synonyms
5-HT-1C, 5-HT1C, 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled, 5-hydroxytryptamine receptor 1C, serotonin 5-HT-1C receptor, serotonin 5-HT-2C receptor, Serotonin receptor 2C
Uniprot ID
Mouse ortholog
Htr2c (15560)
5-hydroxytryptamine receptor 2C (Q5WRU6)
Alternate
HTR2A
HTR2A
HTR2B
HTR2B
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Variants
Clinical Variant
No data
Financial
Lorcaserin - Arena Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,542 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,873 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more